Summary
In order to find out whether diet and drug therapy of hyperlipidemia changes the course and outcome of coronary artery desease, patients with angiographically proven coronary artery disease and hyperlipidemia were treated with diet, fenofibrate and colestipol. By reangiography after two to four years three groups of patients could be formed. Those which showed a progression, no change or a regression of coronary artery disease (CAD). These groups had different levels of lipoproteins under therapy. The regression group had lowest and the no change group had lower levels of total cholesterol and low density lipoprotein (LDL)-cholesterol as compared to the progression group. High density lipoprotein (HDL)- cholesterol had an inverse correlation. These results suggest that a lipid lowering therapy improves course and outcome of CAD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anitschkow N (1933) A history of experimentation on arterial atherosclerosis in animals: In Atherosclerosis: A Survey of the Problem. Edited by Cowdry EV. New York: McMillan, 271–322.
Armstrong ML, Warner ED, Conner WE (1970) Regression of coronary atheromatosis in rhesus monkeys. Circ Res 27: 59.
Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L (1987) Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 275: 3233–3240.
Braunsteiner H, Breier CH, Miihlberger V, Drexel H, Herold M, Lisch JH, Knapp E (1985) Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease. Lancet 1: 1242–1243.
Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT (1990) Regression of coronary artery disease as a result of intensive lipid–lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289–1298.
Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Emiston WA, Smink RD, Sawin HS Jr, Campos CT, Hansen BJ, Aip Tuna RN, Karnegis J, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon, AS, Chalmers TC, Posch Group (1990) Effect of partial ileal bypass surgery on mortality and morbitity from coronary heart disease in patients with hypercholesterolemia, report of the program on the surgical control of the hyperlipidemias ( POSCH ). N Engl J Med 323: 946–955.
Cashin-Hemphill L, Ack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH (1990) Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow up. JAMA 264: 3013–3017.
Clarkson TB, Bond MG, Bullock BC, McLaughlin KJ, Sawjer JK (1984) A study of atherosclerosis regression in macaca mulatta. V. Changes in abdominal aorta and carotid and coronary arteries from animals with atherosclerosis induced for 38 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 mg/dl. Exp Mol Pathol 41: 96–118.
Cohn K, Sakai FJ, Langston MF Jr (1975) Effect of clofibrate on progression of coronary desease: a prospective angiographic study in man. Am Heart J 89: 591–589.
Faggiotto A, Ross R, Harker L (1984) Studies of hypercholesterolemia in the non-human primate. I. Changes that lead to fatty streak formations. Arteriosclerosis 4: 323–328.
Hahmann HW, Bunte TH, Hellwig N, Hau U, Becker D, Dyckmans J, Keller HE, Schieffer HJ (1991) Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 67: 957–961.
Kalin MF, Zumhoff B (1990) Sex hormones and coronary disease: a review of the clinical studies. Steroids 55: 330–352.
Kane JP, Malloy MJ, Ports TA, Phillips Nr, Diehl JC, Havel RJ (1990) Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264: 3007–3012.
Kramsch DM, Aspen AJ, Abramowitz BM, Kreimendahl T, Hood WR Jr (1981) Reduction of coronary atherosclerosis by moderate conditioning exercise in monkeys on an atherogenic diet. N Engl J Med 305: 1483–1489.
Nash DT, Gensini G, Esente P (1982) Effect of lipid lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Int J Cardiol 2: 43–45.
Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan M, Kirkeeide RL, Brand RJ, Gould KI (1990) Can lifestyle changes reverse coronary heart desease? The lifestyle heart trial. Lancet 336: 129–133.
Steinmetz A, Kaffarnik H (1992) Medikamentöse Therapie der Hyperlipoproteinaemien. Internist 33: 44–53.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stellwaag, M. et al. (1993). Determinants for Coronary Atherosclerosis Regression. The Marburg Lipid Intervention Trial. In: Steinmetz, A., Schneider, J., Kaffarnik, H. (eds) Hormones in Lipoprotein Metabolism. Recent Developments in Lipid and Lipoprotein Research. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84855-1_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-84855-1_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-55995-5
Online ISBN: 978-3-642-84855-1
eBook Packages: Springer Book Archive